<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB59C39C-D551-4BCF-9AA1-1C32080BEFD5"><gtr:id>AB59C39C-D551-4BCF-9AA1-1C32080BEFD5</gtr:id><gtr:name>Zhejiang University</gtr:name><gtr:address><gtr:line1>388 Yuhangtang Road</gtr:line1><gtr:postCode>310058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B16D710A-5C40-44CA-A796-B37EC8935E99"><gtr:id>B16D710A-5C40-44CA-A796-B37EC8935E99</gtr:id><gtr:name>University of Michigan</gtr:name><gtr:address><gtr:line1>3003 S. State Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13613115-E290-45AC-BAA6-83D88728749C"><gtr:id>13613115-E290-45AC-BAA6-83D88728749C</gtr:id><gtr:name>Xian Jiaotong University</gtr:name><gtr:address><gtr:line1>28 Xianningxi West Road</gtr:line1><gtr:line2>710049</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB59C39C-D551-4BCF-9AA1-1C32080BEFD5"><gtr:id>AB59C39C-D551-4BCF-9AA1-1C32080BEFD5</gtr:id><gtr:name>Zhejiang University</gtr:name><gtr:address><gtr:line1>388 Yuhangtang Road</gtr:line1><gtr:postCode>310058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B16D710A-5C40-44CA-A796-B37EC8935E99"><gtr:id>B16D710A-5C40-44CA-A796-B37EC8935E99</gtr:id><gtr:name>University of Michigan</gtr:name><gtr:address><gtr:line1>3003 S. State Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13613115-E290-45AC-BAA6-83D88728749C"><gtr:id>13613115-E290-45AC-BAA6-83D88728749C</gtr:id><gtr:name>Xian Jiaotong University</gtr:name><gtr:address><gtr:line1>28 Xianningxi West Road</gtr:line1><gtr:line2>710049</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E04275DF-111E-44B5-B7F0-FECA4478B406"><gtr:id>E04275DF-111E-44B5-B7F0-FECA4478B406</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Dorling</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801965"><gtr:id>E545BBCF-53D5-490F-8E22-5B36C43AAE2F</gtr:id><gtr:title>Manipulating the repair response by vascular progenitor cells; a strategy for preventing and treating chronic rejection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801965</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Organ transplantation is a therapeutic success, but allografts fail prematurely, rarely sustaining recipients for their natural lifespan. A major problem is chronic rejection (CR) manifesting in many organs as transplant arteriosclerosis (TA), in which (as in other types of vascular injury) intimal hyperplasia (IH) leads to progressive ischaemia and fibrosis. There is currently no effective treatment for TA or CR. The basic hypothesis for this proposal is that each of us has vascular progenitor (VP) cells capable of repairing damaged blood vessels, but in TA they are inhibited from doing so by inflammatory factors generated by the immune response. The hypothesis arises directly from our current MRC-funded work, in which we have shown that IH can be completely inhibited by preventing the generation or actions of thrombin on the surface of bone marrow-derived VP. These manipulations lead to regeneration of vessel wall architecture, even in the face of an ongoing alloimmune response. We have concluded that thrombin is a critical factor determining how VP respond to repair cues. We postulate that other factors known to impact on TA, such as the ?danger signal? high mobility group box-1 protein, interferon gamma and nitric oxide, do so by influencing the responsiveness of VP to thrombin, thereby affecting the recruitment, phenotype or function of these cells, independently of effects on the alloimmune response. The goal is to define how these factors enhance or inhibit regenerative repair by VP. The specific aims are to; 1) Define the influence of IFN gamma, NO and HMGB-1 on the phenotype, mobilization and recruitment of VP subpopulations after vascular injury; 2) Link the influence of these factors to thrombin generation or responsiveness; 3) Demonstrate that the neointimal disease in TA is due to phenotypic or functional changes in VP independently of the alloimmune injury. These studies will define, for the first time, the relationships between immune effector and vascular repair mechanisms and establish the foundation for a novel therapeutic strategy to prevent or treat CR, based on manipulating the responsiveness of VP. The results of this study will be used directly to influence the design of therapeutic trials in the dialysis and renal transplant populations at the Hammersmith, in whom clinical research into the biology of circulating VP has already begun.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-11</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1600929</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xi'an Jiaotong University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>School of Medicine Xi'an Jiaotong</gtr:department><gtr:description>Lecture tour of China</gtr:description><gtr:id>A2FEFD0B-75F7-4093-931A-993506634E1B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>imAsyQ3D5eA-1</gtr:outcomeId><gtr:partnerContribution>will be mutual cooperation on various projects</gtr:partnerContribution><gtr:piContribution>Lecturing to establish collaborations in research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Transplantation &amp; Immunology</gtr:department><gtr:description>Novartis</gtr:description><gtr:id>801FE341-A81D-43AC-844B-2C96F632E5C4</gtr:id><gtr:impact>Paper in preparation.</gtr:impact><gtr:outcomeId>c4M1W6NeLzi-1</gtr:outcomeId><gtr:partnerContribution>Financial assistance, technical help</gtr:partnerContribution><gtr:piContribution>Two way sharing of data and techniques - including a trip to Basel in August 2011 to visit Novartis Global Research and to give a talk</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Michigan</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Michigan-Flint</gtr:department><gtr:description>University of Michigan, Flint</gtr:description><gtr:id>09856ECD-8E45-45C4-8647-138D762D1EF1</gtr:id><gtr:impact>Contributions to paper published in 2013 - PMID 23516969</gtr:impact><gtr:outcomeId>C7hVX3eDmvu-1</gtr:outcomeId><gtr:partnerContribution>University of Flint have provided the students with all their living expenses</gtr:partnerContribution><gtr:piContribution>Provided a small laboratory project for biology students to come across to UK in last two summers and spend 4-6 weeks in my lab</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xi'an Jiaotong University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Xi'an Jiaotong University, China</gtr:description><gtr:id>5EF9F1B3-58CC-464E-AAA8-06D842DE84C4</gtr:id><gtr:impact>Awarded a King's Worldwide Partnership Fund Award to assist with the collaboration</gtr:impact><gtr:outcomeId>56dd4b22c61703.72771440-1</gtr:outcomeId><gtr:partnerContribution>They will provide the animals and team to assist in performance of experiments</gtr:partnerContribution><gtr:piContribution>Cooperation on a research project which has involved a senior post-doctoral scientist visiting China for 8 weeks</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zhejiang University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Institute of Respiratory Medicine</gtr:department><gtr:description>Lecture tour of China 2</gtr:description><gtr:id>6555F586-DCEF-4D2F-A393-37F36FDD3815</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>tDuUhynGkue-1</gtr:outcomeId><gtr:partnerContribution>Mutual cooperation in research projects</gtr:partnerContribution><gtr:piContribution>Hoping to gain collaborative partners in research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>MRC Centre for Transplantation</gtr:description><gtr:id>551AC3C5-B039-4BBB-A658-9CF1F543C61B</gtr:id><gtr:impact>Being within the MRC Centre, within King's College London, within Guy's Hospital has significantly contributed to success in applications to British Heart Foundation, Kidney Research UK and commercial organisations for research funding.</gtr:impact><gtr:outcomeId>FHAJMkACJEM-1</gtr:outcomeId><gtr:partnerContribution>Increased collaboration with Richard Smith, Steve Sacks, Gio Lombardi and Maria Hernandez-Fuentes. All have had significant intellectual input into the work</gtr:partnerContribution><gtr:piContribution>Team has become emerged within the centre</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Liver Department</gtr:department><gtr:description>Mark Thursz</gtr:description><gtr:id>C9C8643E-E2B3-43EE-9220-40DF1B3309EF</gtr:id><gtr:impact>Abstract at international meeting 2012</gtr:impact><gtr:outcomeId>fsrz5iz3dmq-1</gtr:outcomeId><gtr:partnerContribution>began a new line of enquiry in a model of liver fibrosis, looking at the contribution of coagulation proteins</gtr:partnerContribution><gtr:piContribution>supply of mice. delivery of a seminar, plus intellectual input into the</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to KPA, Guy's Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B39D3D5E-7BA5-4DDE-ADD4-5C5919C0626B</gtr:id><gtr:impact>Lunchtime meeting attended by 50 or so patients, where I talked about my research, including that funded by MRC. Followed by questins and answer session

Increased interest in research by patients</gtr:impact><gtr:outcomeId>hKREqxRfGA9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>KPA visit to MRC Centre labs</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B66496BA-9798-41A3-BD40-FDBA05AF4FD7</gtr:id><gtr:impact>I organised an Open day for the MRC Centre for Transplantation attended by 60 patients. Two members of my laboratory presented the findings of the MRC-funded work to groups of patients throughout the mrning

increased interest in research by patients</gtr:impact><gtr:outcomeId>oEdkjkaQdYE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Profiled in 'Open Heart' blog</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C057C1C-EE7C-4F23-9C66-55280ED8FE6E</gtr:id><gtr:impact>Hoepfully encouraged more people to read the article

I am not aware of any impact yet,</gtr:impact><gtr:outcomeId>566fbe0c7553a5.44245074</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://openheart.circulationjournal.org/2015/04/anthony-dorling-phd.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>258741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK Clinical Training Fellowship to Dr Philippa Dodd</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>E31E84C4-B67F-432D-B51D-CADA1CD2823B</gtr:id><gtr:outcomeId>542aa652217c10.79630856</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship for Dr Hannah Burton</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M01813X/1</gtr:fundingRef><gtr:id>34BF1027-E61A-44DC-8401-02EFC454AB10</gtr:id><gtr:outcomeId>5649b9914e99b2.48396724</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translation Award (Co-applicant with Richard Smith)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8BB04B17-6E15-4EBA-BAB6-3511223BBB46</gtr:id><gtr:outcomeId>Xbi1GNjJjZ9</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1984</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Worldwide Partnership Fund</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>C9D14FDF-95A8-430B-A034-78E80FB2227D</gtr:id><gtr:outcomeId>56dd4a0f023ac0.06199715</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dysfunctional mobilisation of vascular progenitor cells post-kidney transplantation and post-rejection as a correlate to progressive loss of allograft function (Guy's &amp;amp; St Thomas' Charity)</gtr:description><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>E2652C79-09E2-44B6-9BC9-3307CF77800B</gtr:id><gtr:outcomeId>PDvKxoEH8sH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>147307</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Wellcome Pathfinder Award</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>44FA25E6-E494-41C7-BD2A-F87D331625AB</gtr:id><gtr:outcomeId>586e4b8d9f9237.67761190</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>179840</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Determining the importance and predictive value of T and B lymphocyte alloreactivity in the progression of chronic antibody mediated rejection - an analysis of samples from a UK randomised controlled trial.</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>363C0C0B-92C9-4BD3-BA0C-92C93464C360</gtr:id><gtr:outcomeId>XQg1KCT58gs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EME programme award</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>422977F7-5957-4175-8C93-E1B427B43280</gtr:id><gtr:outcomeId>TVXCmmLRVGZ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1690000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital Bid</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D97FD530-2808-4F2B-ADCB-7E57F1CE535B</gtr:id><gtr:outcomeId>X155vhCAuzV</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>483000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project Grant (Co-applicant with G. Lombardi)</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3C94C6D0-CDE7-49A8-A1D2-D87FCED60EC6</gtr:id><gtr:outcomeId>W8a4qDdpMFk</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46667</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Health Partners Challenge Fund</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>King?s Health Partners</gtr:fundingOrg><gtr:fundingRef>R160405</gtr:fundingRef><gtr:id>05E78D2E-A5A2-433C-8643-59ABB6347C16</gtr:id><gtr:outcomeId>586e49c552d2a9.29732366</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>86000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Preventing atherosclerosis by promoting endothelial cell regeneration through anticoagulant expression by smooth muscle progenitors</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>03786F01-8D90-4798-8872-57ED4D339568</gtr:id><gtr:outcomeId>L7tcoEQKrwU0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49997</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phenotype of B cells in patients with Chronic antibody-mediated rejection (Novartis Unrestricted Educational Grant)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>71EE78C7-C56B-4812-B6D7-4F592521B8C7</gtr:id><gtr:outcomeId>dFWaAyacVSf0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel cell-tethered anticoagulants that were based in principle on the genetic tethering that we used in our early experiments</gtr:description><gtr:grantRef>G0801965</gtr:grantRef><gtr:id>EFAF90B9-A6A0-4E48-9DFC-5C5FA1977673</gtr:id><gtr:impact>Has been used to secure Wellcome Trust money to take these compounds through clinical development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>rwkdRHfAaG6</gtr:outcomeId><gtr:patentId>WO2011027175</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel Antithrombotic Compounds</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Faculty, World Transplant Congress 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>76E4F0D5-609B-42DC-AE4B-058CBF7C38A5</gtr:id><gtr:outcomeId>VjScjMggFjX</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisory Panel, BTS annual Meeting 2012</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>35ACBF2D-A975-4421-BA9F-FA771E493F0E</gtr:id><gtr:outcomeId>Acd7bUJUgHA</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Frontiers in Transplantation Course</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EFB910CD-95A9-4B83-A200-1046EF5EDF7B</gtr:id><gtr:outcomeId>Vcy7a75NQDJ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Advisory Committee for the World Transplant Congress 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1D16BA52-6939-4452-B31D-3A324C5F3661</gtr:id><gtr:outcomeId>eW4MMKYbqtM</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>membrane tethered hirulog, developed directly because of our work with the hirudin-trangenic mice.</gtr:description><gtr:id>9F23F252-8B8C-4255-8AED-F08496AFAF5E</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>LSbwUD3vTbc</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Thrombalexin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3E0B493C-5232-4463-988C-2F4EE092B8F8</gtr:id><gtr:title>Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62a6dbdac2e80fac6849082ae2e6a1c"><gtr:id>b62a6dbdac2e80fac6849082ae2e6a1c</gtr:id><gtr:otherNames>Ezzelarab M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54509a6d196b70.22936609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB560482-50D3-400F-BA0B-54F23EF49DF3</gtr:id><gtr:title>B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>551ee8d2f3ef22.29914698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA106B5-5219-4C95-BBB4-903283650510</gtr:id><gtr:title>Current status of xenotransplantation and prospects for clinical application.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1354625542bb6420c24df5c23eec1b56"><gtr:id>1354625542bb6420c24df5c23eec1b56</gtr:id><gtr:otherNames>Pierson RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn><gtr:outcomeId>pm_13695_15_19796067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D690D2B5-63A3-4633-9230-E9420A0F5E22</gtr:id><gtr:title>Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f40bc5b0102e5288d97d23e4c64c60"><gtr:id>55f40bc5b0102e5288d97d23e4c64c60</gtr:id><gtr:otherNames>Shrivastava S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_13695_25_23347132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F312D2B9-2298-4EB8-B32B-7C1419B3F506</gtr:id><gtr:title>Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b6ed6b6741cefbb67001d899975a0ee"><gtr:id>7b6ed6b6741cefbb67001d899975a0ee</gtr:id><gtr:otherNames>Ekser B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>pm_13695_25_22642260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DEA9C97-3953-4664-B495-EC39B31FFE96</gtr:id><gtr:title>Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35301fe05f391b75e52c10db399cae9e"><gtr:id>35301fe05f391b75e52c10db399cae9e</gtr:id><gtr:otherNames>Chan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>QeLxww77H1t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDC2B511-660E-4512-8134-0EF975060028</gtr:id><gtr:title>The roles of thrombin and protease-activated receptors in inflammation.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e22ea8b9a5712de0fb5c6c45e86833"><gtr:id>54e22ea8b9a5712de0fb5c6c45e86833</gtr:id><gtr:otherNames>Ma L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>H5MaJuupriu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0846D7C4-4ADB-4875-8E0D-3730043E2873</gtr:id><gtr:title>Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de086c273c0c67e49e3b833cb39f230"><gtr:id>4de086c273c0c67e49e3b833cb39f230</gtr:id><gtr:otherNames>Barnett AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>pm_13695_25_24188566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>770E32E0-045A-4F7D-8FE7-67BFFC070EC6</gtr:id><gtr:title>Rituximab may not lead to increased infection rates in transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38bfd1de1a52dfc543b4ecf41e0f6dc8"><gtr:id>38bfd1de1a52dfc543b4ecf41e0f6dc8</gtr:id><gtr:otherNames>Drage M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>sta3nM8wvfB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F3A0F47-5907-4FF3-9A27-2A4EFC2E65A5</gtr:id><gtr:title>Optimising long-term graft survival: establishing the benefit of targeting B lymphocytes.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>54818cd6c011b5.32369030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>154DFB95-C811-46CB-B3BD-A8265FB67AA3</gtr:id><gtr:title>Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c701d8e064a4012140c494c65b7417"><gtr:id>a7c701d8e064a4012140c494c65b7417</gtr:id><gtr:otherNames>Dorling A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>DQbaCQBbdxr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2C59EDE-F99F-4B59-900B-93BAD6F6993A</gtr:id><gtr:title>Incidence and Outcome of C4d Staining With Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039435ec9c62b952072970cc24f17401"><gtr:id>039435ec9c62b952072970cc24f17401</gtr:id><gtr:otherNames>Couzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>561354872325b3.57357128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64D93ED3-33FF-4FF9-B1DB-A2827FB81FD8</gtr:id><gtr:title>Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage.</gtr:title><gtr:parentPublicationTitle>BMJ case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b98728d749fb4c4ee449854974b5bd17"><gtr:id>b98728d749fb4c4ee449854974b5bd17</gtr:id><gtr:otherNames>Claridge S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-790X</gtr:issn><gtr:outcomeId>pm_13695_25_22698899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4DA5AC5-B19B-441C-A10B-CC1C30A0AE31</gtr:id><gtr:title>Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f58f43718dfbc575d7b3f2c5eee78620"><gtr:id>f58f43718dfbc575d7b3f2c5eee78620</gtr:id><gtr:otherNames>Hamaoui K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>57c8203128f986.98966112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85D81762-E0F0-4483-8A5A-D461F5631DE7</gtr:id><gtr:title>Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-? production by Th1 cells.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>586b6910df7834.06699112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA8B1FEC-C86B-4678-8C61-FB06528A47B1</gtr:id><gtr:title>Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3678df0cfb946dbb013ff18f1890cba7"><gtr:id>3678df0cfb946dbb013ff18f1890cba7</gtr:id><gtr:otherNames>Willicombe M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>huR1htTT3fC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D138ABAE-4416-4798-BDF8-C031D2D4A12A</gtr:id><gtr:title>The use of eculizumab in renal transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de086c273c0c67e49e3b833cb39f230"><gtr:id>4de086c273c0c67e49e3b833cb39f230</gtr:id><gtr:otherNames>Barnett AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0902-0063</gtr:issn><gtr:outcomeId>pm_13695_25_23516966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F749F2D-3E79-4AF0-80E8-0381A7D0A46F</gtr:id><gtr:title>APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a65dd598c0cffda8550314e8f13a61"><gtr:id>a2a65dd598c0cffda8550314e8f13a61</gtr:id><gtr:otherNames>Xiao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5649bcd7bfe562.89667577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF9E573F-88D4-4449-9403-95A8732D7AF8</gtr:id><gtr:title>Pancreatic-derived pathfinder cells enable regeneration of critically damaged adult pancreatic tissue and completely reverse streptozotocin-induced diabetes.</gtr:title><gtr:parentPublicationTitle>Rejuvenation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c397f545aca8c0d03d35cb9f90d534eb"><gtr:id>c397f545aca8c0d03d35cb9f90d534eb</gtr:id><gtr:otherNames>Stevenson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1684</gtr:issn><gtr:outcomeId>YfBdLEc4fP6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1905F9C8-4973-4426-8B80-235B10D39271</gtr:id><gtr:title>Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>pm_13695_25_24161661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12865299-5AE1-4BCD-A7EA-E5E871A4811A</gtr:id><gtr:title>Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7593586e84d466eee7964296a9687666"><gtr:id>7593586e84d466eee7964296a9687666</gtr:id><gtr:otherNames>Ezzelarab MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn><gtr:outcomeId>5675dce36f192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8DB0C92-8307-496D-8637-320043562698</gtr:id><gtr:title>Renal allograft recipients fail to increase interferon-? during invasive fungal diseases.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_13695_25_22974244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA9C4D07-F073-4D01-8237-C34A3AB9113C</gtr:id><gtr:title>A new and clinically relevant murine model of solid-organ transplant aspergillosis.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a72830ea0c2b656d2b69838ea5d4bae7"><gtr:id>a72830ea0c2b656d2b69838ea5d4bae7</gtr:id><gtr:otherNames>Herbst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_13695_25_23264562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A971DA9-8919-4C7E-8774-91CD7C82F36E</gtr:id><gtr:title>Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2r?null mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a65dd598c0cffda8550314e8f13a61"><gtr:id>a2a65dd598c0cffda8550314e8f13a61</gtr:id><gtr:otherNames>Xiao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>542aa38b6c0392.65911080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DFAFE44-8FFF-4287-8BEB-72E48E3990A8</gtr:id><gtr:title>Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3678df0cfb946dbb013ff18f1890cba7"><gtr:id>3678df0cfb946dbb013ff18f1890cba7</gtr:id><gtr:otherNames>Willicombe M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>C6sKvkmH7v9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84753803-D974-4981-ADA5-B3EBE2139778</gtr:id><gtr:title>B cells in renal transplantation: pathological aspects and therapeutic interventions.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/927def0f127d030a485850e05a8ca7c7"><gtr:id>927def0f127d030a485850e05a8ca7c7</gtr:id><gtr:otherNames>Barnett N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>YcxLZWZwNtr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0C55AD0-EFC3-4B11-882B-95177454CB6B</gtr:id><gtr:title>Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE-/- mice.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>54e08d4f858e24.56400872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>719465A2-89C2-4BDF-88EA-81DC118A9083</gtr:id><gtr:title>Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039435ec9c62b952072970cc24f17401"><gtr:id>039435ec9c62b952072970cc24f17401</gtr:id><gtr:otherNames>Couzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>561354868af283.77176811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA633F64-AAE7-4496-AF61-9ABE0547E825</gtr:id><gtr:title>Inhibition of thrombin receptor signaling on a-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>gxqKcMCR7gT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D7D123A-539B-4086-B75C-3B110ACDEF07</gtr:id><gtr:title>Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f37d17d516a262388eb2f6b8c9a954b"><gtr:id>2f37d17d516a262388eb2f6b8c9a954b</gtr:id><gtr:otherNames>Karegli J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>57c8203157a040.44535310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA57198E-C16D-4E3E-92FE-480148E2C7B6</gtr:id><gtr:title>Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_13695_25_23516969</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801965</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>